<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Prime Medicine, Inc. — News on 6ix</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock</link>
<description>Latest news and press releases for Prime Medicine, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 07 May 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/prime-medicine-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b09478dffbe2df10fbd8.webp</url>
<title>Prime Medicine, Inc.</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock</link>
</image>
<item>
<title>Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates-1</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates-1</guid>
<pubDate>Thu, 07 May 2026 12:00:00 GMT</pubDate>
<description>-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD -- -- Strengthened leadership team with appointment of Svetlana Makhni as Chief Financial Officer -- -- Cash, cash equivalents, investments, and restricted cash of $149.2 million as of March 31, 2026, providing cash runway into 2027 -- CAMBRIDGE, Mass.</description>
</item>
<item>
<title>Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-appoints-svetlana-makhni-as-chief-financial-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-appoints-svetlana-makhni-as-chief-financial-officer-1</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. “We are delighted to welcome Svetlana to Pri</description>
</item>
<item>
<title>Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-full-year-2025-financial-results-and-provides-business-updates-1</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-full-year-2025-financial-results-and-provides-business-updates-1</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment -- -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 -- CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company</description>
</item>
<item>
<title>Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-present-44th-annual-130000632</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-present-44th-annual-130000632</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco, California. A live audio webcast of the pres</description>
</item>
<item>
<title>Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-england-journal-130500638</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-england-journal-130500638</guid>
<pubDate>Sun, 07 Dec 2025 13:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company’s investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD) in the New England Journal of Medicine (NEJM). The data will also be presented in a poster session at th</description>
</item>
<item>
<title>Prime Medicine to Present at 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-present-8th-annual-130000506</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-present-8th-annual-130000506</guid>
<pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 11:15 a.m. ET in Coral Gables, FL. A live audio webcast of the fireside chat will be available</description>
</item>
<item>
<title>Prime Medicine to Present at Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-present-jefferies-global-130000577</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-present-jefferies-global-130000577</guid>
<pubDate>Tue, 11 Nov 2025 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 12:00 noon GMT (7:00 a.m. ET) in London, United Kingdom. A live audio webcast of the fireside cha</description>
</item>
<item>
<title>CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/correction-prime-medicine-reports-third-152100473</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/correction-prime-medicine-reports-third-152100473</guid>
<pubDate>Fri, 07 Nov 2025 15:21:00 GMT</pubDate>
<description>-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 -- -- Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer -- -- Company to host virtual KOL</description>
</item>
<item>
<title>Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-third-quarter-120000597</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-third-quarter-120000597</guid>
<pubDate>Fri, 07 Nov 2025 12:00:00 GMT</pubDate>
<description>-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 -- -- Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer -- -- Company to host virtual KOL</description>
</item>
<item>
<title>Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-appoints-matthew-hawryluk-130100662</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-appoints-matthew-hawryluk-130100662</guid>
<pubDate>Mon, 03 Nov 2025 13:01:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime’s corporate and business development initiatives, corporate strategy, and alliance management functions, advancing the company’s efforts to expand the reach of Prime E</description>
</item>
<item>
<title>Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-host-virtual-kol-200100142</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-host-virtual-kol-200100142</guid>
<pubDate>Thu, 30 Oct 2025 20:01:00 GMT</pubDate>
<description>-- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 --CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson’s Disease. Prime Medicine remains on track to file an investigat</description>
</item>
<item>
<title>Prime Medicine to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-participate-upcoming-investor-120000112</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-participate-upcoming-investor-120000112</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C. Wainwright Genetic Medicines Virtual Conference 2025: Fireside chat will be available to view on demand beginning Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday,</description>
</item>
<item>
<title>Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-second-quarter-120000455</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-second-quarter-120000455</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset -- -- Completed follow-on offering, raising $144.2 million in gross proceeds and extending cash runway into 2027 -- -- Secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to advance Prime Editors for Cystic Fibrosis -- -- Announced leader</description>
</item>
<item>
<title>Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-closing-public-200100659</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-closing-public-200100659</guid>
<pubDate>Fri, 01 Aug 2025 20:01:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did</description>
</item>
<item>
<title>Prime Medicine Announces Pricing of Public Offering</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-pricing-public-013300002</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-pricing-public-013300002</guid>
<pubDate>Thu, 31 Jul 2025 01:33:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cysti</description>
</item>
<item>
<title>Prime Medicine Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-proposed-public-200100786</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-proposed-public-200100786</guid>
<pubDate>Wed, 30 Jul 2025 20:01:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. All o</description>
</item>
<item>
<title>Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-additional-funding-110000067</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-additional-funding-110000067</guid>
<pubDate>Wed, 16 Jul 2025 11:00:00 GMT</pubDate>
<description>-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot Prime Editors may benefit more than 93% of people with CF -- CAMBRIDGE, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative gen</description>
</item>
<item>
<title>Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-strategic-restructuring-123100696</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-strategic-restructuring-123100696</guid>
<pubDate>Mon, 19 May 2025 12:31:00 GMT</pubDate>
<description>-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Directors, named Executive Chair -- -- Implementing cost</description>
</item>
<item>
<title>Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-breakthrough-clinical-123000934</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-announces-breakthrough-clinical-123000934</guid>
<pubDate>Mon, 19 May 2025 12:30:00 GMT</pubDate>
<description>-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- -- Rapid engraftment observed in both neutrophils and platelets -- -- Encouraging safety profile; no serious adverse events related to PM359 -- -- Initiating efforts to explore continued clinical development oppo</description>
</item>
<item>
<title>Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-first-quarter-120000879</link>
<guid isPermaLink="true">https://6ix.com/company/prime-medicine-inc-common-stock/news/prime-medicine-reports-first-quarter-120000879</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>-- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for th</description>
</item>
</channel>
</rss>